

March 23, 2023
Symbio Pharmaceuticals Limited
Fuminori Yoshida
Representative Director
President & Chief Executive Officer
(Securities Code: 4582)

Notice of Appointments to the Board of Directors and substitute member of the Audit & Supervisory Committee, and Appointments of Corporate Officers

TOKYO, Japan, March 23, 2023 - Symbio Pharmaceuticals Limited (Headquarters: Tokyo) today announced appointments to its Board of Directors and one substitute member of the Audit & Supervisory Committee made by resolution of shareholders approved at the 18th Annual General Meeting of Shareholders (the “AGM”), and Representative Director and Corporate Officer appointments approved by the Board of Directors at a board meeting convened following the close of the AGM. The appointments are as follows:

1. Members of the Board of Directors (excluding directors who are Audit and Supervisory Committee members)

Name	Title
Fuminori Yoshida	Representative Director
Shigetoshi Matsumoto	Board Director <Outside>
Bruce David Cheson	Board Director <Outside>
Eiji Ebinuma	Board Director <Outside>

2. Substitute Member of the Audit & Supervisory Committee

Name	Title
Takashi Watanabe	Substitute Member of the Audit & Supervisory Committee <Outside>

3. Corporate Officers

Name	Title
Fuminori Yoshida	Corporate Officer, President and Chief Executive Officer
Takaaki Fukushima	Executive Corporate Officer, Chief Financial Officer
Koji Fukushima	Corporate Officer, Chief Medical Officer
Yoshiharu Torikai	Corporate Officer
Masahiko Okuno (newly appointed)	Corporate Officer
Hiroyuki Horita (newly appointed)	Corporate Officer (will join on April 1, 2023.)

The biographies of the two new corporate officers are as follows:

New Corporate Officer: Masahiko Okuno		
Career	Apr., 1986	Nissan Motor Co., Ltd.
	Jun., 1994	MBA, Harvard University Graduate School of Business Administration
	Jul., 1994	Nissan Finance of America, Inc. (Seconded)
	Jul., 1997	Finance Dept., Nissan Motor Co., Ltd.
	Aug., 1998	Consultant, Bain & Company Inc.
	Sep., 2001	Novartis Pharma K.K. as Finance Manager
	Jan., 2005	Head, Orthopedic and Dermatology Business Unit
	Jun., 2005	CFO, Sandoz K.K. (Seconded)
	Feb., 2008	Manager, Strategic Planning, Novartis Holding (Seconded)
	Jan., 2009	Head, Marketing & Sales Operations Department, Novartis Pharma K.K.
	Jan., 2015	Head, Respiratory Business Franchise, Member of Pharma Executive Committee
	Aug., 2017	Head, Commercial Execution, Member of Pharma Executive Committee
	Aug., 2021	Senior Advisor, Strategic & Commercial Acceleration Department
	Jun., 2022	Resigned from Novartis Pharma K.K.
	Dec., 2022	Symbio, IR Manager and CFO of SPU
	Mar., 2023	Corporate Officer, Head of Corporate Strategy Div. and CFO of SPU

New Corporate Officer: Hiroyuki Horita		
Career	Apr., 1988	Nippon Chemiphar Co., Ltd.
	Nov., 1993	Novo Nordisk Pharma Co., Ltd.
	Apr., 2000	Manager, Aichi Iyaku Daiikka, Nagoya Branch
	Jan., 2002	Area Manager, Aichi Area, Chubu Block
	Jan., 2003	Block Director, Kanto Daini Block
	Jan., 2007	Sales Director, Norditropin Group
	Jan., 2009	Block Director, Kanto Daiichi Block
	Sep., 2014	Board of Director, Head of Sales Division
	Jan., 2019	Board of Director, Head of Business Development Division
	Apr., 2021	Sumitomo Dainippon Pharma Co., Ltd., Special Assignment for Diabetes Area* (* Name change to Sumitomo Pharma on April 1, 2022)
	Mar., 2023	Sumitomo Pharma (Planned March 31, 2023)
	Apr., 2023	Symbio, Corporate Officer and Sales Division Head (Planned)

[Contact]

Investor Relations

Tel: +81(0)3 5472 1125